1 BTC
=
- USD
AtaiBeckley Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About AtaiBeckley Inc. Common Stock
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Market Statistics
BTC Treasury Info
Trading Metrics
How to Buy ATAI
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ATAI
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesAtaiBeckley Inc. (NASDAQ: ATAI), a clinical-stage biotechnology company developing mental health treatments, announced participation in four major investor conferences in June 2026, including the Jefferies Global Healthcare Conference, Oppenheimer CNS and Neuro-Muscular Summit, HCW Neuro Perspectives Conference, and UBS Virtual CNS Day. The company is advancing its pipeline including BPL-003 for treatment-resistant depression in Phase 3 planning, VLS-01 and EMP-01 in Phase 2 development.
AtaiBeckley reported expanded Phase 2a trial results for EMP-01 (oral R-MDMA) in social anxiety disorder, demonstrating 49% responder rates and clinically meaningful improvements across multiple symptom measures (LSAS, SPIN, SAFE) with a favorable safety profile and no serious adverse events. The treatment showed a 38% reduction in patient-reported symptoms versus 15% on placebo, with durability observed after just two administrations over 28 days.
AtaiBeckley Inc. announced that Co-Founder and CEO Dr. Srinivas Rao will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13-16) and the Needham Virtual Psychedelics Forum (April 27). The company's lead candidate BPL-003 (mebufotenin benzoate nasal spray) has received FDA Breakthrough Therapy Designation and is on track to enter Phase 3 studies in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA.
AtaiBeckley Inc. announced peer-reviewed Phase 2a results for BPL-003 (mebufotenin benzoate nasal spray) in treatment-resistant depression, showing a mean MADRS score reduction of 12.6 points by Day 2 that was sustained over 12 weeks. The drug demonstrated a 54.5% response rate and 63.6% remission rate with good tolerability. The Phase 3 program remains on track for initiation in Q2 2026 following a successful FDA End-of-Phase 2 meeting.
AtaiBeckley announced Q4 2025 financial results with $220.7M in cash runway through early 2029. The company received FDA approval to advance BPL-003 (mebufotenin benzoate nasal spray) into Phase 3 trials for treatment-resistant depression, with initiation planned for Q2 2026. EMP-01 (oral R-MDMA) met primary safety objectives in a Phase 2a social anxiety disorder trial with clinically meaningful efficacy improvements. VLS-01 Phase 2 data is anticipated in H2 2026.